Monosaccharide derivative, monosaccharide-modified boron medicine and preparation method and application of monosaccharide-modified boron medicine
By combining monosaccharide-modified boron drugs with disodium thiol decahydrododoroborate, the high metabolic demand of tumor cells is used to solve the problem of insufficient targeting of boron compounds in boron neutron capture treatment, and achieve more efficient tumors Cell accumulation and therapeutic effects reduce side effects.
Patent Information
- Application Number
- CN202410787940.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-05
AI Technical Summary
In the treatment of boron neutron capture, existing boron compounds have problems such as insufficient tumor targeting, different cell accumulation, large side effects, and low tolerated doses, which are difficult to meet the needs of efficient tumor treatment.
Develop a monosaccharide modified boron drug to design new boron delivery agents to enhance the tumor cell targets of boron drugs by combining with disodium thiol decahydrododoroborate (BSH) oriented and accumulating ability.
It improves the accumulation and treatment effect of boron drugs in tumor cells, reduces toxicity to normal cells, enhances tumor specificity, reduces the side effects of treatment, and provides more efficient boron delivery and retention capabilities.
Smart Images

Figure CN118894892A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a monosaccharide derivative, a monosaccharide-modified boron drug, and a preparation method and application thereof. Background Art
[0002] Malignant tumors are one of the major diseases that threaten human life and health. At present, the three major means of treating tumors clinically are surgery, chemotherapy and radiotherapy. Among them, surgery is an effective means of treating primary tumors, but it is limited to cancer cells that are accessible to surgery, and cancer cells may not be completely eliminated. Chemotherapy is the use of chemical drugs to fight cancer. Through systemic administration, the drugs circulate in the body to kill rapidly dividing cells, especially cancer cells. However, since the drugs are also toxic to normal cells, they usually have significant side effects and can make cancer cells resistant. Traditional radiotherapy uses high-energy ionizing particles such as X-rays, gamma rays or electron beams to destroy cells at the molecular level. It is usually used as a complementary treatment method, such as to eliminate remaining cancer cells after surgery. However, traditional radiotherapy can cause damage to normal tissues near cancer cells or within the radiation field.
[0003] Boron neutron capture therapy (BNCT) is a radiotherapy method for treating malignant tumors that has received widespread attention in recent years. 10 B atoms react with low-energy thermal / epitothermal neutrons to produce alpha particles and 7 Li nuclei, in which the radiation range of alpha particles is limited to less than 10μm, just close to the diameter of a cell, so it can effectively kill tumor cells. The treatment logic of BNCT is different from traditional radiotherapy. 10 B cells will undergo a lethal nuclear reaction, while common nuclei in the human body (such as 12 C and 14 N) is much smaller than the neutron capture cross section 10 B, therefore, normal cells, including those in healthy tissues near the tumor, are less damaged.
[0004] Although BNCT has been clinically applied to the treatment of malignant brain tumors, malignant melanoma, head and neck cancer, and liver cancer, however, scientists have encountered some problems with boron compounds in the clinical application of BNCT. Many types of boron compounds have been reported for BNCT using amino acids, nucleic acids, and liposomes as boron delivery carriers, but only para-boronic acid (BPA) and disodium thiodecahydrododecaborate ([B 12 H n SH] 2-2Na, BSH) are two compounds that are clinically used in BNCT therapy to treat cancer. BPA is an essential amino acid (phenylalanine) analog that can be absorbed by tumor cells through amino acid transporters and enter cells. However, as the extracellular BPA concentration decreases and the intracellular BPA concentration increases, the pumping mechanism will expel BPA out of the cell, so that a significant accumulation difference between normal cells and tumor cells cannot be achieved. At the same time, due to the low boron content of BPA (about 5%), it has certain limitations in the clinical application of BNCT. In contrast, BSH has a higher proportion of boron content, good chemical stability and biocompatibility, and has enhanced permeability and retention (EPR) accumulation in the tumor area, but less in normal tissues. However, BSH only exists in the intercellular space and does not enter the cell. Therefore, the therapeutic effect of BSH during BNCT is still insufficient.
[0005] In order for BNCT to achieve good therapeutic effects, it is necessary to synthesize boron drugs that meet the following requirements: 1) Low intrinsic toxicity to increase the patient's maximum tolerated dose of boron carriers. (2) The 10B content in tumor tissue is greater than 20ug / g (ppm), that is, at least 109 10B atoms in each tumor cell; (3) High tumor specificity, the ratio of boron concentration in tumor tissue to normal tissue (T / N) and the ratio of boron concentration in tumor to blood (T / B) are both greater than 3; to reduce the side effects of treatment; (4) It can be retained in tumor cells for a long time and cleared from blood and normal tissues at a relatively fast rate. The current bottleneck in the development of BNCT is the development of highly efficient boron-containing drugs.
[0006] To overcome this limitation, several studies have aimed to improve the bioavailability of BSH. For example, Futamura et al. linked 1-amino-3-fluorocyclobutane-1-carboxylic acid (ACBC), a non-natural α-amino acid, to BSH to achieve LAT-mediated specific targeting of tumor cells. 18 F-labeled ACBC (18F-ACBC) was used to monitor the metabolism and biodistribution of boron drugs. In the F98 rat glioma model, the median survival time of rats treated with BNCT after ACBC-BSH delivery was significantly prolonged. In 2014, Michiue et al. connected BSH to a variety of cell-penetrating peptides (CPPs). The accumulation of boron in the glioma cell line (U87-MG) was time- and concentration-dependent, and with the extension of treatment time, BSH could enter the cell nucleus more, enhancing the killing effect of tumor cells. The team also screened out a BSH derivative compound (BSH-11R) containing 8 BSH and poly-11-arginine structures. When U87-MG was treated at a concentration of 10 mmol / L, the boron in the cells was 100% boron. 10The B content reached 5623.7ng / 106 cells. Compared with simple BSH, the cell killing ability of BSH-11R increased by more than 100 times.
[0007] However, there is still room for further improvement in the above methods. For example, amino acids may be rapidly metabolized in the body, and some amino acids have low solubility in water, requiring additional preparations to improve solubility. The large-scale synthesis and purification process of cell-penetrating peptides makes it difficult to ensure product quality and consistency. Therefore, both methods still face huge challenges and difficulties in clinical applications.
[0008] In view of this, the present invention is proposed. Summary of the invention
[0009] The effectiveness of BNCT depends largely on 10 B accumulates specifically in tumor cells, thereby targeting and destroying cancer cells without affecting surrounding healthy tissues and blood. Therefore, it is necessary to develop new drugs with high tumor selectivity. 10 B delivery agents are undoubtedly one of the most important requirements for the success of BNCT. Therefore, there is a need to develop new boron compounds that are easier to synthesize, have long retention times in tumors, and selectively target and destroy tumor cells with minimal damage to normal tissues. In addition, there is a need for more effective methods for treating bone tumors, and related tumors, and more specifically, there is a need for more effective boron delivery compounds for BNCT treatment.
[0010] Based on the fact that tumor cells have different sugar metabolism from normal cells, the present invention prepares a monosaccharide-modified BSH small molecule boron drug to increase the cellular uptake of BSH, thereby improving the BNCT therapeutic effect.
[0011] Based on this, the present invention has the following technical solutions: In a first aspect, the present invention first provides a monosaccharide derivative having any of the following structural formulas:
[0012] The present invention synthesizes a new small molecule monosaccharide derivative and uses it to modify the boron drug to achieve the goal of efficient tumor delivery and meet the requirements of BNCT treatment.
[0013] In a second aspect, the present invention provides a method for preparing the monosaccharide derivative, comprising: mixing 4-(N-maleimidomethyl)cyclohexanecarboxylic acid, DIPEA, HATU, a solvent and a monosaccharide and performing an amidation reaction; after the reaction, performing a purification treatment to obtain a glucose derivative; the monosaccharide comprises acetylglucosamine, acetylaminoazidomannose, acetylaminogalactose or acetylaminofucose.
[0014] In the present invention, the CAS number of the acetylglucosamine is 17460-45-6; the CAS number of acetylaminoazidomannose is 1213701-11-1; the CAS number of acetylaminogalactose is 653600-56-7; and the CAS number of acetylaminofucose is 115509-87-0.
[0015] Preferably, the preparation method of the monosaccharide derivative comprises: mixing 4-(N-maleimidomethyl)cyclohexanecarboxylic acid, DIPEA, HATU, DMF and the monosaccharide and performing an amidation reaction at 60-80° C.; after the reaction, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and the crude product obtained by reduced pressure distillation is purified by a reverse purification instrument.
[0016] More preferably, in the purification process, phase A is acrylonitrile, and phase B is a 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B.
[0017] Preferably, the molar ratio of 4-(N-maleimidomethyl)cyclohexanecarboxylic acid to the monosaccharide is (1-1.2):(1-1.2).
[0018] As a preferred technical solution of the present invention, the preparation method of the mono derivative comprises: mixing 90-110 μmol 4-(N-maleimidomethyl)cyclohexanecarboxylic acid, 290-310 μmol DIPEA, 110-130 μmol HATU and DMF, stirring at 20-30° C. for 20-40 min to obtain a mixed solution; then adding 90-110 μmol of the monosaccharide to the mixed solution, stirring at 60-80° C. overnight to perform an amidation reaction; after the reaction is completed, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and the crude product obtained after reduced pressure distillation is purified by a reverse purifier; in the purification process, phase A is acrylonitrile, and phase B is a 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient comprises: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B.
[0019] In a third aspect, the present invention provides a monosaccharide-modified boron drug, which is prepared by the monosaccharide derivative.
[0020] Preferably, the boron drug is disodium mercaptodecahydrogen dodecaborate.
[0021] Preferably, the monosaccharide-modified boron drug includes a compound of any of the following structural formulas:
[0022] The present invention finds that the above-mentioned monosaccharide-modified boron drug has tumor cell targeting and good tumor cell uptake characteristics, and can achieve targeted delivery of BSH to tumor cells, effectively solving the problems of insufficient tumor targeting and poor accumulation ability of BSH in tumor cells during clinical use.
[0023] In a fourth aspect, the present invention provides a method for preparing a monosaccharide-modified boron drug, comprising: mixing the monosaccharide derivative, DIPEA, BSH and a solvent, and performing a thiol addition reaction at 40 to 60° C.; after the reaction, performing a purification treatment to obtain a monosaccharide-modified boron drug.
[0024] Preferably, after the reaction is completed, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and then the crude product obtained by vacuum distillation is purified by a reverse purification instrument.
[0025] More preferably, in the purification process, phase A is acrylonitrile, and phase B is 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B; further preferably, the molar ratio of monosaccharide to BSH is (1-1.2): (1-1.2).
[0026] As a preferred technical solution of the present invention, the preparation method of the monosaccharide-modified boron drug comprises: mixing 0.05-0.15 mmol monosaccharide derivative, 0.25-0.35 mmol DIPEA, 0.05-0.15 mmol BSH, THF and DMF, and performing a thiol addition reaction at 40-60° C.; after the reaction, purifying the monosaccharide-modified boron drug; preferably, after the reaction, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and the crude product obtained by vacuum distillation is purified by a reverse purifier; in the purification process, phase A is acrylonitrile, and phase B is 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient comprises: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B.
[0027] In a fifth aspect, the present invention provides a use of the monosaccharide-modified boron drug in the preparation of BNCT drugs.
[0028] In the present invention, monosaccharide-modified boron drugs have the following advantages in the field of tumor treatment: a) Improve drug delivery efficiency: Since the types and structures of glycoproteins and glycolipids on the surface of tumor cells are different from those of normal cells, monosaccharide-modified drugs designed to target these changes can selectively target tumor cells, help increase drug concentrations at the tumor site, and reduce drug accumulation in normal cells, thereby reducing toxic side effects.
[0029] b) Increased tumor cell uptake: Due to the higher metabolic requirements of tumor cells, including the demand for monosaccharides such as glucose, the corresponding transporter proteins are highly expressed. After the drug is bound to these monosaccharides, it can enter the cell through these transporters.
[0030] c) Potential for diagnostic applications: Monosaccharide-modified diagnostic markers can also be used for in vivo diagnosis of the occurrence, development, distribution and specific location of tumors. The improved diagnostic capabilities provide a good foundation for subsequent tumor treatment.
[0031] In a sixth aspect, the present invention provides a 10 B delivery agent, which includes the monosaccharide modified boron drug.
[0032] In a seventh aspect, the present invention provides an anti-tumor drug, which includes the monosaccharide-modified boron drug.
[0033] In an eighth aspect, the present invention provides use of the monosaccharide-modified boron drug in BNCT treatment.
[0034] In the present invention, when the monosaccharide-modified boron drug is used in BNCT treatment, it is not limited to the injection method, and can include intravenous injection, intravenous drip, intraperitoneal injection, intramuscular injection, subcutaneous injection, intradermal injection, intratumor injection, etc.
[0035] The glucose derivatives, monosaccharide-modified boron drugs, and preparation methods and applications thereof provided by the present invention synthesize new small molecule monosaccharides and use them to modify boron drugs to increase the cellular uptake of BSH, meet the goal of efficient tumor delivery, and thus improve the BNCT treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0037] Figure 1 The amidated glucose derivative in Example 1 provided by the present invention, namely (2R,3S,4S,5R,6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate 1 H-NMR spectrum.
[0038] Figure 2 It is a MALDI-TOF MS chart of the amidated glucose derivative in Example 1 provided by the present invention, namely (2R,3S,4S,5R,6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate.
[0039] Figure 3 It is a MALDI-TOF MS image of the boron drug (glu-BSH) modified with an amidated glucose derivative in Example 2 provided by the present invention.
[0040] Figure 4 This is the MALDI-TOF-MS chart of the amidated mannose derivative in Example 3 provided by the present invention, namely rac-(2R,3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyltriacetate.
[0041] Figure 5 It is a MALDI-TOF MS chart of the amidated mannose sugar-modified boron drug in Example 3 provided by the present invention.
[0042] Figure 6 It is a MALDI-TOF MS chart of the amidated acetylgalactose of the monosaccharide derivative in Example 5 provided by the present invention.
[0043] Figure 7 This is a MALDI-TOF MS graph of BSH modified with an amidated acetylgalactose derivative in Example 6 provided by the present invention.
[0044] Figure 8 This is a MALDI-TOF MS graph of the amidated acetylfucose of the monosaccharide derivative in Example 7 provided by the present invention.
[0045] Fig. 9 This is a MALDI-TOF MS graph of BSH modified with an amidated acetylfucose derivative in Example 8 provided by the present invention.
[0046] Fig.10 It is a quantitative result diagram of the cellular uptake of boron content of BSH provided by the present invention and the boron drug modified with amidated monosaccharide derivative (glu-BSH) prepared in Example 2. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0048] Example 1
[0049] This embodiment provides a glucose derivative having the following structural formula:
[0050] The synthesis method thereof includes: (1) Experimental materials and equipment
[0051] The main reagents and instruments used in this experiment are listed in Tables 1 and 2: Table 1 List of chemical reagents and solvents required for the experiment
[0052] Table 2 List of instruments required for the experiment
[0053] (2) Synthesis Path
[0054] The synthetic route of (2R,3S,4S,5R,6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyltriacetate is as follows:
[0055] (3) Synthesis steps
[0056] Synthesis of (2R,3S,4S,5R,6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyltriacetate: 4-(N-maleimidomethyl)cyclohexanecarboxylic acid (23.7 mg, 100 μmol), DIPEA (21.9 mg, 300 μmol), HATU (45.6 mg, 120 μmol) and DMF (1 mL) were added to an 8 mL sample bottle and stirred at room temperature for 30 min. After adding 1,3,4,6-tetra-O-acetyl-BD-glucosamine (34.7 mg, 100 μmol) to the above system, the reaction was stirred at 70 °C overnight. After the reaction, water (2 mL) was added to the system, and the organic phase was collected after extraction with ethyl acetate (2×5 mL). The crude product obtained after reduced pressure distillation by a rotary evaporator was purified by a reverse purification instrument. In the purification process, phase A is acrylonitrile, and phase B is a 0.8% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B, gradually increasing to 90 vol% phase B, and the collected product is freeze-dried to obtain a white solid (2R, 3S, 4S, 5R, 6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (23 mg, 40.6 μmol), with a yield of 40.6%. Ms=[MH]=565.
[0057] 1 H NMR(400MHz,DMSO-d6)δ,ppm:7.85-7.84(d,1H),7.901(s,2H),5.72-5.70 (d,2H),5.18-5.14(m,2H),4.90–4.88(m,1H),4.20-4.16(m,2H),4.00-3.9 2(m,3H),3.23–3.22(m,2H),2.02-2.01(d,6H),1.98(s,3H),1.89(s,3H),1 .62–1.57(m,4H),1.52-1.51(m,1H),1.24-1.20(m,2H),0.92-0.84(m,2H).
[0058] (4) Characterization
[0059] Nuclear magnetic resonance hydrogen spectrum: Weigh 5-10 mg of sample and dissolve it in deuterated dimethyl sulfoxide. Use 400Mz Bruker AVANCE nuclear magnetic resonance spectrometer to measure the 1H NMR nuclear magnetic hydrogen spectrum of the sample, and analyze it with the help of MestReNova v5.3.1 software to determine the structure of the molecule. The characterization results are shown in Figure 1 .
[0060] Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS): The target product was prepared into a 1 mg / mL methanol solution and the relative molecular weight of the sample was tested. The characterization results are shown in Figure 2 .
[0061] Example 2
[0062] This embodiment provides a monosaccharide-modified boron drug, which is obtained through the following reaction path:
[0063] The synthesis steps include: (2R,3S,4S,5R,6S)-6-(acetoxymethyl)-3-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (56.6 mg, 0.1 mmol, DIPEA (303 mg, 0.3 mmol) was dissolved in THF (1 mL) and DMF (1 mL) and added to an 8 mL sample bottle, and finally BSH (22.2 mg, 0.1 mmol) was added. The reaction was stirred at 50°C overnight. After the reaction was completed, water (2 mL) was added to the system, and the organic phase was collected after extraction with ethyl acetate (2×5 mL). The crude product obtained after reduced pressure distillation by a rotary evaporator was purified by a reverse purifier. In the purification process, phase A was acrylonitrile, and phase B was 0.8% trifluoroacetic acid aqueous solution; the gradient included: starting from 10 vol% phase B, gradually increasing to 90 vol% phase B, and the collected product was freeze-dried to obtain a pale yellow solid target product (50 mg, 67.5 μmol) with a yield of 67%. Ms=[MH]=739.
[0064] The characterization results are shown in Figure 3 .
[0065] Example 3
[0066] This embodiment provides a monosaccharide derivative having the following structural formula:
[0067] The synthesis method thereof includes: (1) Experimental materials and equipment
[0068] The main reagents and instruments used in this experiment are shown in Tables 3 and 4: Table 3 List of chemical reagents and solvents required for the experiment
[0069] Table 4 List of instruments required for the experiment
[0070] (2) Synthesis Path
[0071] The synthetic route of rac-(2R,3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate is as follows:
[0072] (3) Synthesis steps
[0073] Synthesis of rac-(2R,3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate: 4-(N-maleimidomethyl)cyclohexanecarboxylic acid (23.7 mg, 100 μmol), DIPEA (21.9 mg, 300 μmol), HATU (45.6 mg, 120 μmol) and DMF (1 mL) were added into an 8 mL sample vial and stirred at room temperature for 30 min. After adding 1,3,4,6-tetra-O-Α-acetyl-N-azidoacetylamino mannose (100 μmol) to the above system, the reaction was stirred overnight at 70°C. After the reaction was completed, water (2 mL) was added to the system, and the organic phase was collected after extraction with ethyl acetate (2×5 mL). The crude product obtained after reduced pressure distillation by a rotary evaporator was purified by a reverse purification instrument. In the purification process, phase A is acrylonitrile, and phase B is a 0.8% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B, gradually increasing to 90 vol% phase B, and the collected product is freeze-dried to obtain a white solid rac-(2R,3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate, with a yield of 38.1%. Ms=[MH]=623.
[0074] (4) Characterization
[0075] Matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS): The target product was prepared into a 1 mg / mL methanol solution and the relative molecular weight of the sample was tested. The characterization results are shown in Figure 4 .
[0076] Example 4
[0077] This example provides a boron drug modified with amidated mannose in Example 3, which is obtained by the following reaction path:
[0078] The synthesis steps include: preparing rac-(2R,3S,4R,5S,6R)-6-(acetoxymethyl)-3-(2-(4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)cyclohexane-1-carboxamido)acetamido)tetrahydro-2H-pyran-2,4,5-triyl triacetate (0.1mmol, DIPEA (303mg, 0.3mmol) was dissolved in THF (1mL) and DMF (1mL) and added to an 8mL sample bottle, and finally BSH (22.2mg, 0.1mmol) was added. The reaction was stirred at 50°C overnight. After the reaction was completed, water (2mL) was added to the system, and the organic phase was collected after extraction with ethyl acetate (2×5mL). The crude product obtained after reduced pressure distillation by a rotary evaporator was purified by a reverse purifier. During the purification process, phase A was acrylonitrile, and phase B was 0.8% trifluoroacetic acid aqueous solution; the gradient included: starting from 10vol% phase B, gradually increasing to 90vol% phase B, and the collected product was freeze-dried to obtain a pale yellow solid target product (50mg) with a yield of 67%. Ms=[MH]=797.
[0079] The characterization results are shown in Figure 5 .
[0080] Example 5
[0081] This embodiment provides a monosaccharide derivative (amidated acetylgalactose) having the following structural formula:
[0082] The synthesis method is the same as that in Example 1, except that the monosaccharide in Example 1 is replaced by acetylgalactosamine, and the yield of the monosaccharide derivative is 85.23%.
[0083] The characterization results are shown in Figure 6 .
[0084] Example 6
[0085] This example provides a boron drug modified with amidated acetylgalactose in Example 5, which has the following structural formula:
[0086] It was obtained by the same reaction path as Example 2, except that the monosaccharide derivative in Example 2 was replaced by the amidated acetylgalactose prepared in Example 5, with a yield of 79.68%. Figure 7 .
[0087] Example 7
[0088] This embodiment provides a monosaccharide derivative (amidated acetyl fucose) having the following structural formula:
[0089] The synthesis method is the same as that in Example 1, except that the monosaccharide in Example 1 is replaced by acetylaminofucose, and the yield of the monosaccharide derivative is 77.89%.
[0090] The characterization results are shown in Figure 8 .
[0091] Example 8
[0092] This example provides a boron drug modified with amidated acetylfucose in Example 7, which has the following structural formula:
[0093] It was obtained by the same reaction path as Example 2, except that the monosaccharide derivative in Example 2 was replaced by the amidated acetyl fucose prepared in Example 7, with a yield of 81.02%. The characterization results are shown in Fig. 9 .
[0094] Test example
[0095] In vitro cell uptake experiments were conducted on BSH and the monosaccharide-modified BSH prepared in Example 2. The results are as follows: Fig.10 shown.
[0096] Tumor cells were inoculated in 6-well plates and adhered overnight. Monosaccharide-modified BSH with different boron concentrations (0, 50, 100, 200, 500, 1000 μg / mL) was added and incubated for 24 hours. After completion, the supernatant was discarded, the cells were washed with PBS and collected, and the boron content in the cells was determined by ICP-MS after digestion.
[0097] The quantitative results using ICP showed that the intracellular boron content of glu-BSH (monosaccharide-modified BSH prepared in Example 2) after incubation at different concentrations was significantly greater than that of BSH.
[0098] The experiment found that the monosaccharide-modified BSH prepared in Examples 4, 6, and 8 can increase the cellular uptake of BSH, meet the goal of efficient tumor delivery, and thus improve the BNCT therapeutic effect. Similarly, the effects of other monosaccharide-modified BSH in the present invention are comparable to those of glu-BSH in Example 2; due to space limitations, they will not be described in detail here.
[0099] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A monosaccharide derivative, characterized in that: It has any of the following structural formulas:
2. The method for preparing the monosaccharide derivative according to claim 1, characterized in that: include: 4-(N-maleimidomethyl)cyclohexylcarboxylic acid, DIPEA, HATU, a solvent and monosaccharide are mixed and subjected to an amidation reaction; after the reaction, a purification treatment is performed to obtain a glucose derivative; the monosaccharide includes acetylglucosamine, acetylaminoazidomannose, acetylgalactosamine or acetylaminofucose.
3. The method for preparing a monosaccharide derivative according to claim 2, characterized in that: include: 4-(N-maleimidomethyl)cyclohexanecarboxylic acid, DIPEA, HATU, DMF and the monosaccharide are mixed and subjected to an amidation reaction at 60-80° C.; after the reaction, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and the crude product obtained by reduced pressure distillation is purified by a reverse purifier; preferably, during the purification process, phase A is acrylonitrile, and phase B is a 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B; preferably, the molar ratio of 4-(N-maleimidomethyl)cyclohexanecarboxylic acid and the monosaccharide is (1-1.2):(1-1.2).
4. A monosaccharide-modified boron drug, characterized in that: The monosaccharide derivative is prepared by the monosaccharide derivative described in claim 1.
5. The monosaccharide-modified boron drug according to claim 4, characterized in that: The boron medicine is disodium mercaptodecahydrogen dodecaborate.
6. The monosaccharide-modified boron drug according to claim 4, characterized in that: A compound comprising any of the following structural formulas:
7. A method for preparing a monosaccharide-modified boron drug, characterized in that: include: The monosaccharide derivative, DIPEA, BSH and solvent are mixed, and a thiol addition reaction is carried out at 40-60° C.; after the reaction, a purification treatment is carried out to obtain a monosaccharide-modified boron drug; preferably, after the reaction, water is added to the reaction system, and the organic phase is collected after extraction with ethyl acetate, and the crude product obtained by vacuum distillation is purified by a reverse purification instrument.
8. The method for preparing a monosaccharide-modified boron drug according to claim 7, characterized in that: During the purification process, phase A is acrylonitrile, and phase B is a 0.7-0.9% trifluoroacetic acid aqueous solution; the gradient includes: starting from 10 vol% phase B and gradually increasing to 90 vol% phase B; more preferably, the molar ratio of monosaccharide to BSH is (1-1.2): (1-1.2).
9. Use of the monosaccharide-modified boron drug according to any one of claims 5 to 7 in the preparation of BNCT drugs.
10. A 10 B delivery agent, characterized in that The monosaccharide-modified boron drug comprises any one of claims 5 to 7.
